Yondelis + Yondelis + Dexamethasone + Dexamethasone
Phase 2Completed 0 watching 0 views this week⚡ Active
52
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Liposarcoma
Conditions
Liposarcoma, Leiomyosarcoma
Trial Timeline
May 1, 2003 → May 1, 2008
NCT ID
NCT00060944About Yondelis + Yondelis + Dexamethasone + Dexamethasone
Yondelis + Yondelis + Dexamethasone + Dexamethasone is a phase 2 stage product being developed by Johnson & Johnson for Liposarcoma. The current trial status is completed. This product is registered under clinical trial identifier NCT00060944. Target conditions include Liposarcoma, Leiomyosarcoma.
Hype Score Breakdown
Clinical
17
Activity
12
Company
10
Novelty
5
Community
5
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00060944 | Phase 2 | Completed |
Competing Products
12 competing products in Liposarcoma
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Abemaciclib + Placebo | Eli Lilly | Phase 3 | 77 |
| efatutazone | Daiichi Sankyo | Phase 2 | 52 |
| Eribulin Mesylate | Eisai | Phase 1 | 33 |
| Trabectedin + Dexamethasone | Johnson & Johnson | Phase 2 | 52 |
| HDM201 + LEE011 | Novartis | Phase 1 | 33 |
| pazopanib | Novartis | Phase 2 | 52 |
| PF-07220060 + Midazolam | Pfizer | Phase 2 | 51 |
| Sunitinib Malate (SU011248) | Pfizer | Phase 2 | 51 |
| Cabazitaxel | Sanofi | Phase 2 | 51 |
| INCMGA00012 + Palbociclib | Incyte | Phase 2 | 49 |
| Selinexor + Placebo | Karyopharm Therapeutics | Phase 2/3 | 57 |
| Selinexor + Ixazomib | Karyopharm Therapeutics | Phase 1 | 25 |